CD52 and neoplasm: Moreover, we found that alemtuzumab, an anti-CD52 antibody, induced stronger ADCC in K562–FLT3ITD/WT cells compared with that in K562–FLT3WT/WT cells (Fig. 6a, b) and dramatically suppressed tumor growth by K562–FLT3ITD/WT cells in mouse xenograft experiments (Fig. 6c, d).